pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
192
stories
16d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
16d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
16d
Pfizer to make $2.5B in new cost cuts
endpoints
17d
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
17d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
17d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
21d
Alnylam plunges as earnings deliver ‘one-two punch’
biopharma dive
21d
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
endpoints
21d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
22d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
23d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
23d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
24d
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
fiercebiotech
24d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
24d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
28d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
28d
FDA panel confronting peptide controversy
stat
29d
Make or break: Commercial hires critical for success
biospace
29d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
← prev
page 2 of 7
next →
